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One approach to understanding the molecular basis of the cellular interactions that 
take place during the immune response is to identify and characterize the cell-surface 
glycoproteins of the cell types involved to identify molecules that may play a  role in 
these  processes.  In  man,  cell-surface  glycoproteins  of  thymus-dependent  (T)  and 
thymus-independent  (B)  lymphocytes and lymphoblastoid cell lines have previously 
been analyzed by a combination of various surface-labeling techniques, immunopre- 
cipitation with conventional xenoantisera, and analysis by sodium dodecyl sulphate- 
polyacrylamide gel  electrophoresis  (SDS-PAGE) t  (1-3).  Comparison of the  surface 
proteins of HSB2, a human T  leukemic cell line, and CCRF-SB, a normal B cell line 
from the same patient, by these methods, revealed characteristic differences in their 
high molecular weight surface molecules: the B cell line expressed a molecule with an 
apparent  molecular weight  of ~220,000,  whereas  HSB2  cells expressed a  molecule 
with  an apparent  molecular weight  of 200,000  (1).  Similar  differences in  the  high 
molecular weight  glycoproteins of normal  human  T  and  B  lymphocytes have also 
been reported (2, 3). 
Recently, the monoclonal antibody technique (4) has greatly facilitated the analysis 
of surface molecules of human  lymphoid cells  (5).  With  this technology, we report 
here data that demonstrate the differences between the high molecular weight surface 
molecules of human T  and B cells can be accounted by the presence of structurally 
distinct  but antigenically related glycoproteins on their cell surface. Chemical char- 
acterization, including two-dimensional peptide mapping, shows that these glycopro- 
teins are the human homologues of murine T200 glycoprotein (6, 7). 
Materials and Methods 
Cell  Lines  and  Tissues.  All cultured human cell lines, including CCRF-HSB2 (8), a T  cell 
line  established from a  patient with a  T  cell-acute lymphocytic leukemia; CCRF-SB  (9), a 
normal B cell line from the same patient as CCRF-HSB2; and CCRF-CEM (10), another T 
cell-leukemic cell line, were grown in RPMI-1640 medium (Grand Island Biological Co., Grand 
Island, N. Y.) supplemented with ,5-10% fetal calf serum. Mouse T lymphoma cell lines, ASL1 
and BW5147 (11), were maintained in Dulbecco's modified Eagle's medium supplemented with 
10% horse serum. Homogenates from tissues obtained at postmortem within a  few hours of 
death and stored at  -70°C  were prepared at 4°C with an Omni mixer (Ivan Sorvall,  Inc., 
Norwalk,  Conn.) followed by filtration through nylon gauze and extensive  washing with 0.15 
M NaCI-0.01  M phosphate buffer (pH 7.2). Peripheral blood lymphocytes were isolated  from 
defibrinated blood by FicolI-Hypaque gradient centrifugation (! 2). Granulocytes were isolated 
from peripheral blood by mixing 40 ml of defibrinated blood with 20 ml of 5% (wt/vol) dextran 
• Supported by  National Cancer Institute  grants CA-20272 and  CA-21993 and  by  the  Clayton 
Foundation for Research, California Division. 
1  Abbreviations used in this paper: H-BSS, Hepes-buffered  balanced salt solution; PBS, phosphate-buffered 
saline; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide  gel electrophoresis. 
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(clinical grade; Sigma Chemical  Co., St. Louis, Mo.) in Hepes-buffered balanced salt solution 
(H-BSS). After a 30-min incubation at 37°C, the leukocyte-rich supernate  was removed, and 
a cell pellet was obtained by centrifugation.  The ceils were washed  twice with H-BSS, then 
layered over Ficoll-Hypaque. After centrifugation,  the granulocyte-rich  cell pellet obtained was 
treated  with Tris-buffered  NH4CI to lyse contaminating erythrocytes  (13). 
Immunological Reagents and Procedures.  Monoclonal antibody T29/33  was obtained  from  a 
fusion of spleen cells from BALB/c mice immunized against the human cell line, CCRF-CEM, 
with  the  nonproducer myeloma cell line, S I94/5.XXO.BU. 1 by standard  procedures  (4,  7). 
Immunoprecipitation studies were carried out with ascitic fluid from tumor-bearing mice. The 
procedures used were essentially as described in detail previously (14). Trace antibody binding, 
quantitative immunofluoreseence with the fluorescence-activated cell analyzer, and absorption 
assays were done as previously described,  except  for minor modifications  (7,  15). For these 
experiments, monoclonal  T29/33 antibody from culture supernate was used. For immunoflu- 
orescence studies  of frozen tissue sections, portions  of tissue were obtained from  surgery  or 
postmortem  and rapidly frozen. Cryostat-frozen  sections, 5-#m thick, were collected on acid- 
cleaned  microscope slides, air-dried  for  30 min,  and  rehydrated  for  10  rain  in  Dulbecco's 
phosphate-buffered  saline  (PBS). The sections were  then  flooded  with  the  undiluted  tissue 
culture  supernate  that contained the monoclonal  antibodies.  After a  l-h incubation at room 
temperature,  they were given three rinses of 10 rain each with PBS and incubated for another 
hour  with  fluorescein  isothiocyanate-conjugated  goat  anti-mouse  IgG at  a  I:I00 dilution 
(Antibodies Inc., Davis, Calif.). After another 10-min rinse with PBS, they were cover-slipped 
with Gelvatol  (Monsanto  Co., St. Louis, Mo.) and examined  and photographed with a Zeiss 
fluorescence microscope (Carl Zeiss, Inc., New York) equipped with an HBO 50-W light source 
and BG3 excitation  filter. Sections incubated with  supernates  that contained unrelated  anti- 
bodies or PBS were used as negative controls. 
Biochemical Procedures.  Lactoperoxidase-catalyzed  iodination,  metabolic labeling with L-[35S] 
methionine,  and  proteolysis  studies  were  carried  out  as  described  previously  (14). Peptide 
mapping analysis  was also  performed  as  described  previously  for  studies  of murine  T200 
glycoprotein  (14), except  that  labeled  protein  Staphylococcus aureus immunoprecipitates  were 
reduced  and carboxymethylated before preparative  SDS-PAGE. This modification  improves 
the recovery of labeled protein  and gives identical  maps to the procedure  used previously. 
Results 
Identification  of the Human Homologue of Murine  T200 Glycoprotein.  Previous studies 
had shown that  human T  and B  lymphoid cells exhibited  differences in  their high 
molecular weight surface glycoproteins detected by surface-labeling techniques and 
immunoprecipitation (1-3). These observations are similar to those obtained in earlier 
studies of the cell-surface glycoproteins of mouse lymphoid cells (6, 7). In the mouse, 
we now know that the differences in the high molecular weight proteins of T  and B 
lymphocytes detected by analysis on SDS-PAGE are attributable  to the presence of 
structural  variants  of the  glycoprotein referred  to  as  T200  (7,  15). We  therefore 
investigated whether the differences in high molecular weight glycoproteins of human 
T  and B cells could be accounted for by a human homologue of murine T200. 
A monoclonal antibody against a  possible candidate for the human homologue of 
T200 glycoprotein was obtained from a  fusion of mouse spleen cells immunized with 
the human T  cell line, CCRF-CEM, with the mouse myeloma, S 194/5.XXO.BU. 1 as 
described in Materials and Methods. In preliminary experiments, by trace antibody 
binding  and/or  indirect  immunofluorescence,  this  antibody,  designated  T29/33, 
reacted  with  41  of 45  human  hematopoietic  cell  lines  tested  and  with  >95%  of 
peripheral  blood mononuclear cells  and  granulocytes. A  labeled  molecule with  an 
apparent  molecular weight  of ~200,000,  which, on  the  basis  of metabolic-labeling 
studies  with  mannose and  galactose is  a  glycoprotein, was precipitated  by T29/33 844  HUMAN T200 GLYCOPROTEIN 
monoclonal antibody from a lysate of iodinated CCRF-CEM cells (data not shown). 
When similar iodination experiments were carried  out with HSB2  and CCRF-SB 
cells, as shown in Fig.  1, the antibody precipitated a  glycoprotein with an apparent 
molecular weight of ~220,000  from the B cell line, CCRF-SB, and a  glyeoprotein 
with an apparent  molecular weight of 200,000  from the T  cell-leukemic cell line, 
HSB2. Thus, the differences in the high molecular weight glycoproteins of CCRF-SB 
and HSB2 cells previously detected by conventional xenoantisera can be explained 
by these two antigenically related glycoproteins. 
Comparison of [anS]Methionine T~yptic Peptides  from Murine T200 and the Glycoprotein of 
Human Lymphoid Cells Defined by T29/33 Monoclonal Antibody.  The results reported in 
the previous section suggested that T29/33  monoelonal antibody may indeed react 
with the human homologue of murine T200 glycoprotein. To investigate this possi- 
bility, murine T200 glyeoprotein and the putative human homologue were labeled 
with  [aSS]methionine, isolated by immunoprecipitation and  SDS-PAGE,  and their 
tryptic peptides compared by two-dimensional tryptic peptide analysis. Two murine 
T  cell-leukemic  cell  lines,  ASL1  and  BW5147,  were  used  as  a  source  of T200 
glycoprotein; the human glycoprotein was isolated from HSB2 cells or another human 
T  cell-leukemic cell  line, CCRF-CEM.  No  differences were  detected  between  the 
tryptic peptides from the glycoproteins isolated from the two different cell lines from 
each species.  As shown in Fig.  2,  the labeled tryptic peptides obtained from T200 
glycoprotein were as previously reported (14). It is clear from a comparison with those 
of the  human  glycoprotein  that  both  molecules  share  a  substantial  number  of 
methionine-containing tryptic peptides. This was confirmed by analysis of a mixture 
of the peptides of both molecules. We estimate that 17 labeled peptides are shared by 
the mouse and human glyeoproteins, 15 peptides are unique to murine T200, and 13 
peptides are unique to the human homologue. 
Tissue Distribution of Human T200  Glycoprotein Homologue.  In  the  mouse,  T200 
glycoprotein appears to be restricted to cells of the hematopoietic series.  Within the 
hematopoietic system, however, the glycoprotein is broadly distributed, being present 
on T  and B lymphocytes, myeloid cells and their precursors, and immature erythroid 
cells. We have investigated the tissue distribution of the human T200 homologue by 
trace-antibody binding  ,  quantitative absorption,  and  quantitative immunofluores- 
cence with the fluorescence-activated cell analyzer and immunofluorescence micros- 
copy of frozen sections.  As  described  earlier,  the glycoprotein is  found in  various 
amounts on the majority of human hematopoietic cell lines and on >95% of peripheral 
blood  leukocytes. A  similar broad  distribution  was  found in  other lymphoid and 
hematopoietic tissues examined, which included spleen, thymus, bone marrow, and 
tonsil. As shown in Fig. 3, immunofluorescence microscopy of frozen sections of tonsil 
and spleen revealed strong and relatively uniform staining of all the lymphoid cells 
present in both organs. 
The  distribution  of human  T200  glyeoprotein  on  nonhematopoietic  cells  was 
investigated by quantitative absorption with tissue homogenates and intact cells. As 
shown  in  Table  I,  the  glycoprotein was  not  detected  on  brain,  liver,  kidney, or 
erythrocytes. As found previously for other monoclonal antibodies (7), the absorption 
test  was  relatively insensitive, and  the  lower  limit  of detection  was  ~10%  of the 
amount of the  glycoprotein expressed  on  the  human  spleen  cells.  Except  for  the 
occasional lymphoid cell, however, we did not detect fluorescent staining of any cell FIG.  1.  Immunoprecipitation of T29/33  glycoprotein from laSI-labeled CCRF-HSB2 and CCRF- 
SB cells. The autoradiograph of a  10%  SDS-polyacrylamide gel of immunoprecipitates prepared 
from  lysates  of CCRF-HSB2  (tracks  a  and  c)  and  CCRF-SB  cells  (tracks  b  and  d)  is  shown. 
Antibodies: a  and b, T29/33  monoclonal antibody plus goat anti-mouse IgG; c and d, goat anti- 
mouse IgG alone as control. Mr, apparent molecular weight. 
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TABLE  I 
Tissue Distribution of Human T200 Glycoprotein 
Tissue 
Relative  Immunoflu-  amount of 
glycoprotein  orescence 
Spleen  1.0  +++ 
Kidney  <0~ 12  -* 
Liver  <0.12  - 
Brain  <0.12  - 
Erythrocytes  <0.04  - 
Lung  ND:I:  - 
Adrenal  ND  - 
Myocardium  ND  - 
Prostate  ND  - 
Breast fibroadenoma  ND  - 
Tonsil  ND  +++ 
RAJI Burkitt's lymphoma cell line  0.26  ND 
CCRF-CEM T cell-leukemic cell line  0.33  ND 
The results of quantitative absorption experiments and indirect immunoflu- 
orescence  studies  of cryostat  tissue  sections  are shown.  For  quantitative 
absorption, equal volumes ofT29/33 antibody at a dilution that was limiting 
in the trace  antibody-binding assay were  incubated for  1 h  at  4°C with 
various  amounts of cells or  tissue  homogenates and  vortexed  at  15-min 
intervals. The mixtures were centrifuged, and the supernates were assayed in 
duplicate for residual  binding to CCRF-HSB2 cells. The table gives the 
relative absorption calculated from the packed volumes of cells or homoge- 
nate required for 50% absorption of T29/33 antibody. For immunofluores- 
cence, cryostat sections were prepared and stained as described in Materials 
and Methods  and Fig. 3. It should be noted that in many tissues occasional 
lymphocytes  were  found that  stained  strongly with  T29/33  monoclonal 
antibody. All tissues were stained with an anti-,O2-microglobulin monoclonal 
antibody. 
Negative except for lymphoid cells. 
Not determined. 
type in frozen sections of a  variety of nonhematopoietic tissues, which suggests that 
the  glycoprotein  is  only  expressed  in  significant  quantities  on  hematopoietic  cells 
(Table I). 
Proteolysis of Human  7"200  Glycoprotein.  The  structural  relationship of mouse  and 
human  T200  glycoproteins  was  examined  further  by  proteolysis  experiments.  We 
have  previously  shown  that  after  solubilization  in  Nonidet  P-40,  murine  T200 
glycoprotein  is  rapidly  cleaved  by  trypsin  and  several  other  proteases  to  give  a 
protease-resistant  fragment with an apparent  molecular weight  of ~  100,000  (14).  A 
similar fragment can be obtained in low yield by treating intact cells with proteases. 
The  results of trypsin treatment  of the  human  T200  homologue on intact  HSB2 
cells  or  after  solubilization  in  Nonidet  P-40  are  shown  in  Fig.  4.  Treatment  of 
iodinated HSB2 cell lysates with trypsin for 20 min gave two labeled fragments with 
apparent  molecular weights  of ~  1 I0,000  and  70,000  in  good  yield  (Fig.  4).  These 
fragments were resistant to further degradation by trypsin because similar results were 
obtained with a  60-min incubation (data not shown). Treatment  of intact cells with 
trypsin, in contrast to murine T200 glycoprotein, also led to the quantitative cleavage 
of the  human  homologue.  Under  these  conditions, only the  labeled  70,000-mol  wt 
fragment was obtained. Unlike the proteolytic fragment of murine T200 glycoprotein OMARY,  TROWBRIDGE,  AND  BATTIFORA  849 
Fro.  4.  Trypsin digestion of l~I-labeled human T200 homologue.  HSB2  cells  were  labeled by 
lactoperoxidase-catalyzed iodination as described in Materials and Methods. Labeled cells (1 X 10  ¢ 
cells in 1.0 ml of 0.15 M  NaCI-0.01  M  phosphate buffer [pH 7.2]) were either directly treated with 
trypsin (80 #g/ml for 10 min at 23°(2) or first soluhilized at the same cell concentration in 0.15 M 
NaCI-0.01  M phosphate buffer that contained 1% Nonidet P-40 and then digested with trypsin (50 
#g/ml for 20 min at 23°G). Proteolysis was terminated by addition of phenylmethylsulfonyl fluoride 
and ovomucoid trypsin inhibitor. After immunoprecipitation, samples were analyzed by electropho- 
resis  in a  10% SDS-polyacrylamide gel.  Shown is the autoradiograph of gel  tracks:  (a)  T29/33 
glycoprotein from untreated cells, (b) T29/33 glycoprotein treated with trypsin after solubilization, 
(c) T29/33  glycoprotein isolated from the incubation supernate after trypsin digestion of intact 
cells, (d) immunoprecipitation control in which T29/33 antibody was omitted, and (e) proteolysis 
inhibition control in which protease inhibitors were added to a sample of cell lysate before addition 
of trypsin. (Track e is identical to inhibition control of T29/33 on intact cells, which is not shown.) 
Mr, apparent molecular weight. 
that  remains  associated  with  the  cell  pellet  after  trypsinization  (14),  the  tryptic 
cleavage product of the human  glycoprotein is released almost  quantitatively  from 
the cell surface (Fig. 4). 
Discussion 
The results reported in this paper demonstrate that the differences in high molecular 
weight glycoproteins of human T and B cells detected by surface labeling and analysis 850  HUMAN T200 GLYCOPROTEIN 
by SDS-PAGE can be accounted for by the presence on human hematopoietic cells 
of a  homologue of murine T200 glycoprotein. In both species, the glycoprotein is a 
major cell-surface component that is broadly distributed on hematopoietic cells but 
that has not been detected on other tissues. At present, structural homology between 
species  has only been clearly established for a  few other cell-surface glycoproteins of 
lymphoid cells:  immunoglobulin, histocompatibility antigens, Ia, and Thy-I  glyco- 
proteins;  and,  in  the case  of Thy-1,  there  are  significant differences in  the  tissue 
distribution  of  the  homologous  glycoproteins  in  different  species  (16-19).  T200 
glycoprotein, like these other surface glycoproteins, may be present in many species. 
In the rat, a major cell-surface glycoprotein referred to as leukocyte-common antigen, 
which is almost certainly a  rat homologue of T200 glycoprotein, has been isolated 
and characterized by Sunderland et  al.  (20).  In  both  species of rodent, structural 
polymorphisms of the glycoprotein homologues have been  identified; in the mouse 
the polymorphism is defined by the Ly-5 alloantigenic system (21),  in  the rat  by 
alloantisera  against  ART  and  Ly-1  (22).  It  is  not  known  whether  an  analogous 
polymorphism exists in man. Furthermore, it is not known whether antibodies against 
the human glycoprotein will generally exhibit selective cytotoxicity for thymocytes 
and mature T  ceils,  as is the case in rat and mouse (15,  22).  Until these points are 
clarified,  the  possible  clinical  uses  of monoclonal  antibodies  against  the  human 
homologue cannot be completely assessed. 
The results of the peptide-mapping analysis suggests that  the structure of T200 
glycoprotein is highly conserved between mouse and man. Although a  quantitative 
estimate of homology requires comparison of the primary sequences of the murine 
and human glycoproteins, the number of overlapping peptides is a good indication of 
extensive sequence  homology. This  is  particularly  true  because  peptide-mapping 
analysis tends to underestimate similarities in structure. For example, neither human 
~- and I¢-immunoglobulin light chains nor the a-  and fl-subunits of hemoglobulin 
shares common tryptic peptides even though primary sequence analysis reveals 37% 
homology between  }~-  and  r-chains  and  44%  homology between  the  subunits  of 
hemoglobin  (23-25).  It  is interesting that, in  contrast  to Thy-1, Ia and  the major 
histocompatibility antigens, even conventional xenoantisera raised in rabbits, show 
little or no cross-reactivity between murine T200 glycoprotein and the human and rat 
homologues (26) (I. S. Trowbridge. Unpublished results.). One possibility compatible 
with this observation and the peptide mapping data is that a substantial portion of 
the molecule is highly conserved between species, whereas the remaining fraction, at 
least part of which is exposed on the cell surface, has undergone extensive modification 
during phylogeny. The proteolysis experiments suggest the human homologue differs 
in structure from murine T200 in the region of the molecule external to the plasma 
membrane, although they give no indication of how extensive these differences may 
be. 
In common with most cell-surface glycoproteins, the functions ofT200 glycoprotein 
and  its homologues are  not  known. The  fact that  the  glycoprotein appears  to  be 
restricted  to  hematopoietic cells  in  several  species  strengthens  the  belief that  the 
molecule serves some role related to the functions of this cell type. We have previously 
suggested  that  T200  glycoprotein  may  be  involved  in  determining  the  different 
patterns of migration of murine T  and B cells, although there is presently no direct 
evidence to support  this suggestion (26).  Kasai et al.  (27)  have previously reported OMARY, TROWBRIDGE, AND BATTIFORA  851 
that Ly-5 antiserum specifically inhibits murine natural killer activity in vitro in the 
absence of complement, thus  raising the possibility that  T200  glycoprotein and  its 
homologues  may  be  involved  in  cell-mediated  cytolysis.  Recently,  a  monoclonal 
antibody that appears to be specific for the structural  form of T200 glycoprotein on 
activated  murine T  cells has been  obtained  (M.  Sarmiento.  Unpublished  results.). 
This monoclonal antibody, in particular, and those against determinants common to 
both T  and  B  cells in  mouse, rat, and humans  that  we and others  have obtained, 
should be useful reagents to investigate the biological role of murine T200 glycoprotein 
and its homologues in other species. 
Summary 
We report the identification of the human homologue of murine T200 glycoprotein. 
Peptide-mapping experiments suggest that the structure of the glycoprotein is highly 
conserved between the two species. Many of the properties of human T200 homologue 
are similar to those of murine T200 glycoprotein: it is broadly distributed within the 
hematopoietic system but is not detectable on nonhematopoietic cells; there are also 
structural  differences  between  the  forms  of the  glycoprotein  found  on  T  and  B 
lymphoblastoid cell  lines.  These results  suggest  the  homologous glyeoproteins may 
play similar functional roles in both species. 
We thank Theresa Ferson and Cathie Mazauskas for skilled technical assistance. We also thank 
Dr. Paul Wolf, University Hospital, San Diego, for providing clinical  material. 
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